Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi maintains a Neutral rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and raises the price target from $10 to $12.
August 09, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Paul Choi maintains a Neutral rating on Phathom Pharmaceuticals and raises the price target from $10 to $12.
The raised price target from $10 to $12 by a reputable analyst at Goldman Sachs is likely to have a positive short-term impact on Phathom Pharmaceuticals' stock price, despite the Neutral rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100